Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma
Interventions: BIOLOGICAL: Bevacizumab|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Placebo Administration|OTHER: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Collaborators: Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group